Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In

Quick Launch

Jeffrey Probstfield

JEFFREY L. PROBSTFIELD, MD, FACP, FACC, FESC

Professor of Medicine
Adjunct Professor of Epidemiology, School of Public Health
Director, Clinical Trials Service Unit
 

University of Washington Medical Center
1959 N.E. Pacific Street
Box 356422
Seattle, WA 98195-6422



EDUCATION AND TRAINING

  • Trainee in Clinical Pharmacology, University of Minnesota Hospitals, Minneapolis, MN, 1973
  • Graduate School, Dept. of Pharmacology, University of Minnesota, Minneapolis, MN, 1976
  • Fellow, University of Minnesota Hospitals, Minneapolis, MN, 1971
  • MD, University of Washington School of Medicine, Seattle, WA, 1967
  • Intern, Hennepin County General Hospital, Minneapolis, MN, 1968
  • BA, Pacific Lutheran University, Tacoma, WA, 1963

 

 BOARD CERTIFIC​ATION

  • Project Officer's Course (Advanced), NHLBI, 1990
  • Project Officers' Course (Basic), NHLBI, 1985
  • American Board of Internal Medicine, 1973
  • National Board of Medical Examiners, 1968

 

 AREAS OF CLINICAL EXP​ERTISE

  • Treatment of Hyperlipidemia
  • Treatment of High Blood Pressure

 

 SPECIAL ACCOMPLI​SHMENTS

  • U.S. Investigators' Committee, CHARM
  • U.S. Coordinator: INTERHEART, OASIS7/CURRENT, COMPASS, REWIND Trials
  • PI AIM-HIGH, AIMHIGH COORDINATING CENTER Trials
  • PI FLAT-SUGAR
  • Teaching: - Biostat 524: Design of Clinical Studies (School of Public Health Course on Clinical Trials)

 

 

CURRENT RESEARCH IN​TERESTS

 

 Selected Publications

 
 
Pitt B, et al. The TOPCAT Trial Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 313:731
 
 
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun D, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Result. From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014;114.3850
 
 
 
The ORIGIN Trial Investigators. Predictors of Nonsevere and Severe hypoglycaemia during glucose lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care 2014:37:1329.
 
 
 
Bordeleau L, et al. The ORIGIN Trial Investigators. The effect of basal insulin glargine and/or n-3 fatty acids on incident cancers in patients with dysglycemia. Diabetes Care. Diabetes Care 2014;37:1468.
 
 
 
Jose-Miguel Yamal et. al Stroke outcomes among participants randomized to chlorthalidone, amlodipine or Lisinopril in ALLHAT. Am J Hyper 2014 08.003.
 
 
 
Pfeffer, M. A., Claggett, B. Assmann, S. F., Boineau, R., Anand, I. S., Clausell, N., Pitt, B. (2014). Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015;131:34-42.
 
 
 
The FLAT-SUGAR Trial Investigators. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 diabetes. Diabetes Care 2015; 38:1558-1566. (Chair: Writing Committee)
 
 
 
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif J-C for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247-2257
 
 
 
Barbra Ricker, Katherine Seymour, Alexander Arslan, April Slee, Ruth McBride, Jeffrey Probstfield; Evaluating the Effect of Therapy Masking. Applied Clinical Trials 2015: October/November 24-32.
 
 
 
ORIGIN Trial Investigators; Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care 2015;38::1676